Rice Researchers Test New Approach to Protect Transplanted Insulin-Producing Cells

In Type 1 diabetes, the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. For decades, researchers have explored transplanting healthy pancreatic islet cells as a potential way to restore natural insulin production and reduce the burden of daily diabetes management.

However, transplants face a major obstacle: the recipient's immune system recognizes the new cells as foreign and attacks them. To prevent this, patients typically must take immunosuppressant drugs for life—medications that come with significant side effects and health risks.

Researchers at Rice University's Veiseh lab are testing a different strategy. Instead of suppressing the entire immune system, they're developing small capsules made from alginate—a natural material derived from seaweed—that would house the transplanted islet cells alongside engineered support cells.

The innovation lies in what happens inside these capsules. The engineered support cells secrete anti-inflammatory proteins that calm the local immune response right at the transplant site, reducing both immune attack and the scarring (fibrosis) that often causes implants to fail over time.

This approach builds on earlier work by the Veiseh team demonstrating that modulating the local immune environment using engineered cells is a viable strategy. The team has shown that by locally controlling inflammation at the transplant site, they may be able to eliminate the need for systemic immunosuppressant therapy.

With a new two-year award from Breakthrough T1D, a leading global Type 1 diabetes research organization, the researchers will now refine and test the encapsulation platform in more detail to move closer to potential clinical use.

If this research proves successful, it could offer a meaningful improvement in the lives of people living with Type 1 diabetes. By reducing or eliminating the need for immunosuppressant drugs, patients could potentially avoid the infections, kidney problems, and other complications that come with long-term immune suppression.

It's important to note that this work is still in the research and testing phase. Many promising laboratory approaches do not advance to clinical use, and timelines for human testing remain uncertain. However, this research represents an active effort to address one of the major barriers to making islet cell transplantation a more practical option for more people.

Origin: Rice News | News and Media Relations | Rice University (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.